1
|
Chen C, Pan N, Chen Z, Gou C, He X, Wang M, Chen B, Zhou Z, Ren Q, Zhong Y, Xiang Y, Zhao S, Yan Y, Song T. The GG genotype of rs743572 in CYP17A1 gene regulating the decrease of T/E ratio can be an independent risk factor for MetS-BPH: a retrospective cohort study. World J Urol 2024; 42:439. [PMID: 39046536 PMCID: PMC11269469 DOI: 10.1007/s00345-024-05138-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Accepted: 06/21/2024] [Indexed: 07/25/2024] Open
Abstract
PURPOSE To confirm if the CYP17A1 gene regulates the ratio of T/E leading to MetS-BPH. METHODS 824 men, aged 47-88 years, were recruited into this study through consecutive routine physical examination programs and long-term outpatient screening. Several parameters, including SNPs of CYP17A1 gene, total testosterone, estradiol, and the ratio of total testosterone to estradiol (T/E) were obtained for each participant. Based on the diagnosis of BPH, MetS, and MetS-BPH, the participants were divided into BPH and non-BPH groups, MetS and non-MetS groups, and MetS-BPH and non-MetS-BPH groups. Values of the obtained parameters were evaluated using one-way analysis of variance, Student's t-test, Chi-squared test, and logistic regression analysis. RESULTS SNPs of the CYP17A1 gene, including the rs743572 genotypes (GG, GA, and AA), rs3781287 genotypes (GG, GT, TT), and rs4919686 genotypes (CC, CA, and AA), were present in every group. Only the GG genotype of rs743572 was independently associated with BPH (OR = 5.868, 95% CI: 3.363-7.974, P < 0.001), MetS (OR = 7.228, 95% CI: 3.925-11.331, P < 0.001), and MetS-BPH (OR = 3.417, 95% CI: 1.783-5.266, P < 0.001) after adjusting for age. In the population of genotype GG of rs743572, the decrease in T/E ratio was an independent risk factor for BPH (OR = 839.756, 95% CI: 36.978-1334.263, P = 0.001), MetS (OR = 376.988, 95% CI: 12.980-488.976, P < 0.003), and MetS-BPH (OR = 388.236, 95% CI: 24.869-495.363, P = 0.003). CONCLUSION The GG genotype of rs743572 in CYP17A1 gene regulating the decrease of T/E ratio can be an independent risk factor for MetS-BPH populations. TRIAL REGISTRATION NUMBER ChiCTR2200057632 "retrospectively registered". DATE OF REGISTRATION March 15, 2022 "retrospectively registered".
Collapse
Affiliation(s)
- Congcong Chen
- Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China
| | - Ningrui Pan
- Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China
| | - Zongping Chen
- Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China.
| | - Chengren Gou
- Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China
- Department of Urology, People's Hospital of Wuchuan County, Wuchuan, Guizhou, 564300, China
| | - Xu He
- Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China
| | - Min Wang
- Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China
| | - Bo Chen
- Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China
| | - Zidong Zhou
- Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China
| | - Qixu Ren
- Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China
| | - Youzhuang Zhong
- Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China
| | - You Xiang
- Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China
| | - Sicong Zhao
- Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China
| | - Yong Yan
- Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China
| | - Tao Song
- Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China
- Department of Urology, Eastern Hospital, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, 610101, China
| |
Collapse
|
2
|
Li S, Chen Y, Xie L, Meng Y, Zhu L, Chu H, Gu D, Zhang Z, Du M, Wang M. Sex hormones and genetic variants in hormone metabolic pathways associated with the risk of colorectal cancer. ENVIRONMENT INTERNATIONAL 2020; 137:105543. [PMID: 32059146 DOI: 10.1016/j.envint.2020.105543] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Revised: 02/02/2020] [Accepted: 02/02/2020] [Indexed: 06/10/2023]
Abstract
OBJECTIVE The different incidence of colorectal cancer between the sexes suggests that sex hormones may be involved in the susceptibility to colorectal cancer. The association between sex hormones and genetic variants in hormone metabolic pathways and the colorectal cancer risk remains unclear. METHODS We detected sex hormone levels in plasma from colorectal cancer patients and controls in males by ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). We evaluated the clinical significance of sex hormones on colorectal cancer diagnosis with the area under the receiver operating characteristic curve (AUC). The role of genetic variants in hormone metabolic pathways in the colorectal cancer risk was assessed by a logistic regression model. The biological functions were detected by luciferase reporter assays and cell behavior experiments. RESULTS We found that 2-methoxyestrone (2-MeO-E1) was highly expressed in cases (PFDR = 3.48 × 10-19). The expression of 2-MeO-E1 in plasma showed improved accuracy for predicting colorectal cancer (AUC = 0.88). In the 2-MeO-E1 metabolic pathway, rs165599 in COMT was significantly associated with an increased risk of colorectal cancer (P = 0.009). Mechanistically, we found that the rs165599 G allele could decrease the binding ability of miR-22-3p to the COMT 3'-UTR. Furthermore, knockdown of COMT inhibited cell proliferation, induced cell apoptosis and arrested the cell cycle in the G1 phase. CONCLUSION This is the first study to show that 2-MeO-E1 and a genetic variant in COMT contribute to the susceptibility to colorectal cancer. These results shed light on the different incidence of colorectal cancer between the sexes.
Collapse
Affiliation(s)
- Shuwei Li
- State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China; Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Yehua Chen
- State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China; Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Lisheng Xie
- Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China; Department of Infection Control, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China
| | - Yixuan Meng
- Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Lingjun Zhu
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Haiyan Chu
- Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Dongying Gu
- Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Zhengdong Zhang
- Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Mulong Du
- Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China; Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Meilin Wang
- State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China; Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
| |
Collapse
|
3
|
Santric V, Djokic M, Suvakov S, Pljesa-Ercegovac M, Nikitovic M, Radic T, Acimovic M, Stankovic V, Bumbasirevic U, Milojevic B, Babic U, Dzamic Z, Simic T, Dragicevic D, Savic-Radojevic A. GSTP1 rs1138272 Polymorphism Affects Prostate Cancer Risk. ACTA ACUST UNITED AC 2020; 56:medicina56030128. [PMID: 32183092 PMCID: PMC7143748 DOI: 10.3390/medicina56030128] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Revised: 02/28/2020] [Accepted: 03/09/2020] [Indexed: 12/24/2022]
Abstract
Background and Objectives: One of the most frequent genetic alterations reported to date in prostate cancer (PC) is aberrant methylation of glutathione transferase P1 (GSTP1). Taking into consideration the involvement of oxidative stress in PC pathogenesis and recent advances in scientific understanding of the role of GSTP1*Ala114Val rs1138272 polymorphism in carcinogenesis, we hypothesized that this single-nucleotide polymorphism (SNP) influences the risk of PC independently of, or in combination with, other GST polymorphisms, including GSTP1*IIe105Val rs1695 or GSTM1 and GSTT1 deletion polymorphisms. Materials and Methods: Genotyping was performed in 237 PC cases and in 236 age-matched controls by multiplex polymerase chain reaction (PCR) for deletion of GST polymorphisms and by quantitative PCR for SNPs. Results: We found that carriers of either GSTP1*Val (rs1138272) or GSTP1*Val (rs1695) variant alleles had a PC risk compared to individuals with both referent alleles (OR = 4.93, 95%CI: 2.89–8.40, p < 0.001 and OR = 1.8, 95%CI: 1.19–2.73, p = 0.006, respectively). Additionally, in a haplotype analysis we found that individuals with GSTP1*C haplotype, represented by both variant alleles (GSTP1*Val rs1695 + GSTP1*Val rs1138272), had a 5.46 times higher risk of PC development compared to individuals with the most frequent haplotype (95%CI = 2.56–11.65, p < 0.001), suggesting a potential role of those variants in PC susceptibility. A regression analysis on the number of risk-associated alleles per individual (GSTM1*active, GSTT1*null, GSTP1*Val rs1695 and GSTP1*Val rs1138272) showed a significant increase in the risk of developing PC, from 3.65-fold in carriers of two risk alleles (95%CI = 1.55–8.61, p = 0.003) to an approximately 12-fold increase in carriers of all four risk alleles (95%CI = 3.05–44.93, p < 0.001). Conclusion: Prostate cancer may be influenced by multiple glutathione transferase (GST) polymorphic genes, especially GSTP1, highlighting the role of gene–gene interactions in human susceptibility to this cancer.
Collapse
Affiliation(s)
- Veljko Santric
- Clinic of Urology, Clinical Center of Serbia, 11000 Belgrade, Serbia; (V.S.); (M.A.); (U.B.); (B.M.); (U.B.); (Z.D.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Milica Djokic
- Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia; (M.D.); (M.N.); (V.S.)
| | - Sonja Suvakov
- Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia; (S.S.); (M.P.-E.); (T.R.); (T.S.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Marija Pljesa-Ercegovac
- Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia; (S.S.); (M.P.-E.); (T.R.); (T.S.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Marina Nikitovic
- Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia; (M.D.); (M.N.); (V.S.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Tanja Radic
- Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia; (S.S.); (M.P.-E.); (T.R.); (T.S.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Miodrag Acimovic
- Clinic of Urology, Clinical Center of Serbia, 11000 Belgrade, Serbia; (V.S.); (M.A.); (U.B.); (B.M.); (U.B.); (Z.D.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Vesna Stankovic
- Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia; (M.D.); (M.N.); (V.S.)
| | - Uros Bumbasirevic
- Clinic of Urology, Clinical Center of Serbia, 11000 Belgrade, Serbia; (V.S.); (M.A.); (U.B.); (B.M.); (U.B.); (Z.D.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Bogomir Milojevic
- Clinic of Urology, Clinical Center of Serbia, 11000 Belgrade, Serbia; (V.S.); (M.A.); (U.B.); (B.M.); (U.B.); (Z.D.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Uros Babic
- Clinic of Urology, Clinical Center of Serbia, 11000 Belgrade, Serbia; (V.S.); (M.A.); (U.B.); (B.M.); (U.B.); (Z.D.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Zoran Dzamic
- Clinic of Urology, Clinical Center of Serbia, 11000 Belgrade, Serbia; (V.S.); (M.A.); (U.B.); (B.M.); (U.B.); (Z.D.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Tatjana Simic
- Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia; (S.S.); (M.P.-E.); (T.R.); (T.S.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
- Serbian Academy of Sciences and Arts, 11000 Belgrade, Serbia
| | - Dejan Dragicevic
- Clinic of Urology, Clinical Center of Serbia, 11000 Belgrade, Serbia; (V.S.); (M.A.); (U.B.); (B.M.); (U.B.); (Z.D.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
- Correspondence: (A.S.-R.); (D.D.); Tel.: +381-11-3643-27 (A.S.-R.); Tel: +381-11-366-3062 (D.D.)
| | - Ana Savic-Radojevic
- Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia; (S.S.); (M.P.-E.); (T.R.); (T.S.)
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
- Correspondence: (A.S.-R.); (D.D.); Tel.: +381-11-3643-27 (A.S.-R.); Tel: +381-11-366-3062 (D.D.)
| |
Collapse
|
4
|
Gonthier K, Poluri RTK, Audet-Walsh É. Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer. J Steroid Biochem Mol Biol 2019; 191:105367. [PMID: 31051242 DOI: 10.1016/j.jsbmb.2019.04.016] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Revised: 04/15/2019] [Accepted: 04/17/2019] [Indexed: 12/19/2022]
Abstract
Sex-steroid hormones have been investigated for decades for their oncogenic properties in hormone-dependent cancers. The increasing body of knowledge on the biological actions of androgens in prostate cancer has led to the development of several targeted therapies that still represent the standard of care for cancer patients to this day. In the prostate, androgens promote cellular differentiation and proper tissue development. These hormones also promote the aberrant proliferation and survival of prostate cancer cells. Over the past few years, sequencing technologies for functional genomic analyses have rapidly expanded, revealing novel functions of sex-steroid hormone receptors other than their classic roles. In this article, we will focus on transcriptomic- and genomic-based evidence that demonstrates the importance of the androgen receptor signaling in the regulation of prostate cancer cell metabolism. This is significant because the reprogramming of cell metabolism is a hallmark of cancer. In fact, it is clear now that the androgen receptor contributes to the reprogramming of specific cellular metabolic pathways that promote tumor growth and disease progression, including aerobic glycolysis, mitochondrial respiration, fatty acid ß-oxidation, and de novo lipid synthesis. Overall, beyond regulating development, differentiation, and proliferation, the androgen receptor is also a master regulator of cellular energy metabolism.
Collapse
Affiliation(s)
- Kevin Gonthier
- Department of Molecular Medicine, Axe Endocrinologie - Néphrologie du Centre de recherche du CHU de Québec, Canada; Centre de recherche sur le cancer - Université Laval, Canada
| | - Raghavendra Tejo Karthik Poluri
- Department of Molecular Medicine, Axe Endocrinologie - Néphrologie du Centre de recherche du CHU de Québec, Canada; Centre de recherche sur le cancer - Université Laval, Canada
| | - Étienne Audet-Walsh
- Department of Molecular Medicine, Axe Endocrinologie - Néphrologie du Centre de recherche du CHU de Québec, Canada; Centre de recherche sur le cancer - Université Laval, Canada.
| |
Collapse
|
5
|
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. Nat Commun 2018; 9:4568. [PMID: 30410027 PMCID: PMC6224563 DOI: 10.1038/s41467-018-06920-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Accepted: 10/01/2018] [Indexed: 11/15/2022] Open
Abstract
Benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS) are common conditions affecting the majority of elderly males. Here we report the results of a genome-wide association study of symptomatic BPH/LUTS in 20,621 patients and 280,541 controls of European ancestry, from Iceland and the UK. We discovered 23 genome-wide significant variants, located at 14 loci. There is little or no overlap between the BPH/LUTS variants and published prostate cancer risk variants. However, 15 of the variants reported here also associate with serum levels of prostate specific antigen (PSA) (at a Bonferroni corrected P < 0.0022). Furthermore, there is a strong genetic correlation, rg = 0.77 (P = 2.6 × 10−11), between PSA and BPH/LUTS, and one standard deviation increase in a polygenic risk score (PRS) for BPH/LUTS increases PSA levels by 12.9% (P = 1.6×10−55). These results shed a light on the genetic background of BPH/LUTS and its substantial influence on PSA levels. Elderly males are often affected by benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS), but their link to prostate cancer risk is not well defined. Here, a genome-wide association study of BPH/LUTS patients from Iceland and the UK found 23 significant variants at 14 loci, and 15 of these variants associate with prostate specific antigen, which is linked to prostate cancer risk.
Collapse
|
6
|
Chen ZP, Yan Y, Chen CJ, Li M, Chen C, Zhao SC, Song T, Liu T, Zou CH, Xu Q, Li X. The single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS-BPH). Andrology 2018; 6:568-578. [PMID: 29873201 PMCID: PMC6646917 DOI: 10.1111/andr.12498] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2018] [Revised: 04/01/2018] [Accepted: 04/04/2018] [Indexed: 02/06/2023]
Abstract
Studies have shown that 48.59% of benign prostate hyperplasia (BPH) is combined with metabolic syndrome (MetS). The mainstream view supports the correlation between MetS and BPH, but the pathogenesis of MetS‐BPH is not fully understood. Four hundred and seventy‐four men, aged 47 years or older, were recruited into this study by consecutive routine physical examination programs, and several parameters were obtained from each participant. Based on the diagnosis of BPH, MetS, and MetS‐BPH, the participants were divided into BPH and Non‐BPH groups, MetS and Non‐MetS groups, as well as MetS‐BPH and Non‐MetS‐BPH groups. The values of the obtained parameters were evaluated using Student's t‐test, chi‐square test, and logistic regression analysis. The value of estradiol (E2) was higher in the diseased groups (BPH, MetS, and MetS‐BPH groups) compared with the corresponding control groups (Non‐BPH, Non‐MetS, and Non‐MetS‐BPH groups), and the differences were statistically significant. Also, E2 had an independent association with BPH (OR = 2.286, 95% CI: 1.723–3.593, p < 0.001), MetS (OR = 1.406, 95% CI: 0.585–2.315, p < 0.001), and MetS‐BPH (OR = 1.249, 95% CI: 0.795–1.962, p < 0.001). Regarding SNPs of CYP19A1 gene, both the rs4646 genotypes (CC, CA, and AA) and the rs700518 genotypes (CC, CT, and TT) were present in every group, and all genotypes had statistically significant differences between the diseased and corresponding control groups. However, only the TT genotype of rs700518 was independently associated with BPH, MetS, and MetS‐BPH after adjusting for age. The TT genotype of rs700518 is an independent risk factor for the MetS‐BPH populations, and the CYP19A1 gene regulation of estrogen leads to MetS‐BPH.
Collapse
Affiliation(s)
- Z P Chen
- Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.,Department of Urology, Affiliated Hospital of Zunyi Medical College, Zunyi, China
| | - Y Yan
- Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
| | - C J Chen
- Department of Urology, Affiliated Hospital of Zunyi Medical College, Zunyi, China
| | - M Li
- Department of Urology, Affiliated Hospital of Zunyi Medical College, Zunyi, China
| | - C Chen
- Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
| | - S C Zhao
- Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
| | - T Song
- Department of Urology, Affiliated Hospital of Zunyi Medical College, Zunyi, China
| | - T Liu
- Department of Urology, Affiliated Hospital of Zunyi Medical College, Zunyi, China
| | - C H Zou
- Department of Urology, Affiliated Hospital of Zunyi Medical College, Zunyi, China
| | - Q Xu
- Department of Urology, Affiliated Hospital of Zunyi Medical College, Zunyi, China
| | - X Li
- Department of Urology, Affiliated Hospital of Zunyi Medical College, Zunyi, China
| |
Collapse
|
7
|
Katsarou MS, Giakoumaki M, Papadimitriou A, Demertzis N, Androutsopoulos V, Drakoulis N. Genetically driven antioxidant capacity in a Caucasian Southeastern European population. Mech Ageing Dev 2017; 172:1-5. [PMID: 28844971 DOI: 10.1016/j.mad.2017.08.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Accepted: 08/19/2017] [Indexed: 01/31/2023]
Abstract
Previous studies have underlined the function of specific xenobiotic metabolizing phase-I or phase-II enzymes and endogenous antioxidant-related enzymes in the reduction and/or progression of oxidative stress and consequently the incidence of several diseases. In the present study, 10 polymorphic variants (rs4880, rs1799895, rs660339, rs1050450, rs1001179, rs28665122, rs1695, rs1138272, rs1051740 and rs2234922) were investigated in 1132 individuals of a Caucasian Southeastern European population. The frequency distribution of alleles and genotypes was compared to data of European (Northern, Central, Northwestern and Southwestern) and Global populations, extracted from the ensembl genome browser. The allele frequencies in the case of rs1051740 were similar to the frequencies noted in the global population. The majority of the present study allelic polymorphisms showed similar frequency distribution to those of the European or the Global populations (0.88≤OR≤1.14). The rs1051740 polymorphism demonstrated similar to the Global population frequencies (OR=1.09). In conclusion, observed distributions of the polymorphisms studied in the Southeastern population demonstrate a positive impact (rs4880, rs1799895, rs660339, rs28665122) and a negative impact (rs1050450, rs1138272, rs109179, rs1695) against oxidative stress when compared to other population groups.
Collapse
Affiliation(s)
- Martha-Spyridoula Katsarou
- Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, 15771, Athens, Greece
| | - Maria Giakoumaki
- Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, 15771, Athens, Greece
| | - Andriana Papadimitriou
- Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, 15771, Athens, Greece
| | - Nikolaos Demertzis
- Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, 15771, Athens, Greece
| | - Vasileios Androutsopoulos
- Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, 15771, Athens, Greece
| | - Nikolaos Drakoulis
- Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, 15771, Athens, Greece.
| |
Collapse
|
8
|
Na R, Helfand BT, Chen H, Conran CA, Crawford SE, Hayward SW, Tammela TLJ, Hoffman-Bolton J, Zheng SL, Walsh PC, Schleutker J, Platz EA, Isaacs WB, Xu J. A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Prostate 2017; 77:1213-1220. [PMID: 28656603 PMCID: PMC5565164 DOI: 10.1002/pros.23380] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2017] [Accepted: 06/05/2017] [Indexed: 01/22/2023]
Abstract
BACKGROUND Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) are common conditions. Little is known about their etiologies except that studies have suggested a substantial heritable component. Our objective is to provide a comprehensive, genome-wide evaluation of inherited risks and possible mechanisms of etiology in BPH. METHODS We performed a three-stage, genome-wide association study (GWAS) of men from three independent populations, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial, the CLUE II cohort, and a Finnish hospital-based population. DNA samples were genotyped using the Illumina HumanOmniExpress BeadChip in REDUCE and CLUE II, and using the Sequenom iPLEX system for the confirmation stage in the Finnish population. A logistic regression model was used to evaluate the association between each SNP and BPH/LUTS. RESULTS Fourteen SNPs reached P < 5.0 × 10-4 in the meta-analysis of the two GWASs (CLUE II and REDUCE). A total of 773 SNPs were chosen for the confirmation step in the Finish cohort. Only one SNP (rs17144046) located ∼489 kb downstream of GATA3 remained significant after correction for multiple testing (P < 6.5 × 10-5 ). This SNP marginally reached the GWAS significance level after performing a meta-analysis of the three stages (P-meta = 8.89 × 10-7 ). Expression quantitative trait loci (eQTL) analyses showed that the risk allele (G) of rs17144046 was significantly associated with increased expression of GATA3 (P = 0.017). Reported studies indicated a close correlation between GATA3 and BPH pathogenesis and progression. CONCLUSIONS Rs17144046 located near GATA3 was significantly associated with BPH/LUTS in three independent populations, but did not reach a stringent GWAS significance level. Genetic variants of GATA3 may play a role in the inherited susceptibility and etiology of BPH/LUTS. Further research in this area is needed.
Collapse
Affiliation(s)
- Rong Na
- Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China
- Fudan Universtiy Shanghai Medical College, Shanghai, China
| | - Brian T. Helfand
- Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA
- Department of Surgery, NorthShore University HealthSystem, Evanston, Illinois, USA
| | - Haitao Chen
- Fudan University School of Public Health, Shanghai, China
| | - Carly A. Conran
- Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA
| | | | - Simon W. Hayward
- Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA
| | - Teuvo LJ Tammela
- Department of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland
| | - Judy Hoffman-Bolton
- Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
| | - S. Lilly Zheng
- Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA
| | - Patrick C. Walsh
- Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Johanna Schleutker
- Department of Medical Biochemistry and Genetics, University of Turku, Turku, Finland
| | - Elizabeth A. Platz
- Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
| | - William B. Isaacs
- Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
- Corresponding authors: Dr. Jianfeng Xu. 1001 University Place, Evanston, IL 60201, U.S.A., Phone: (224) 264-7501. Fax: (224) 364-7675. ; Dr. William B. Isaacs, 115 Marburg, Johns Hopkins Hospital, 600 N. Wolfe St. Baltimore, MD 21187, U.SA. Phone: (410)-955-2518. Fax (410)-955-2520.
| | - Jianfeng Xu
- Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China
- Corresponding authors: Dr. Jianfeng Xu. 1001 University Place, Evanston, IL 60201, U.S.A., Phone: (224) 264-7501. Fax: (224) 364-7675. ; Dr. William B. Isaacs, 115 Marburg, Johns Hopkins Hospital, 600 N. Wolfe St. Baltimore, MD 21187, U.SA. Phone: (410)-955-2518. Fax (410)-955-2520.
| |
Collapse
|